Effects of Consumption of Phosphatidylserine on the Cognitive Function

Sponsor
Orthomedico Inc. (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05962008
Collaborator
ECA Healthcare Inc. (Other)
114
2
3
7.8
57
7.4

Study Details

Study Description

Brief Summary

The main objective of this trial is to verify the effects of consumption of phosphatidylserine for 12 weeks on the cognitive function in healthy Japanese subjects.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: DHAPS® product
  • Dietary Supplement: BioPS® product
  • Dietary Supplement: Placebo
N/A

Detailed Description

In this study, the investigators will evaluate the cognitive function before and after the intervention. The groups to be compared are omega-3-phosphatidylserine derived from herring roe, phosphatidylserine derived from soybean, and a placebo.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
114 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Effects of Consumption of Phosphatidylserine on the Cognitive Function: a Randomized, Placebo-controlled, Double-blind, Parallel-group Comparison Study
Anticipated Study Start Date :
Jul 19, 2023
Anticipated Primary Completion Date :
Mar 11, 2024
Anticipated Study Completion Date :
Mar 11, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Omega-3-phosphatidylserine derived from herring roe

Take 300 mg/day of omega-3-phosphatidylserine derived from herring roe.

Dietary Supplement: DHAPS® product
Take 4 capsules per day after breakfast with warm water.

Active Comparator: Phosphatidylserine derived from soybean

Take 300 mg/day of phosphatidylserine derived from soybean.

Dietary Supplement: BioPS® product
Take 4 capsules per day after breakfast with warm water.

Placebo Comparator: Placebo

Take 0 mg/day of phosphatidylserine.

Dietary Supplement: Placebo
Take 4 capsules per day after breakfast with warm water.

Outcome Measures

Primary Outcome Measures

  1. The measured value of the standardized score of composite memory at Week 12 [Week 12]

    Verbal Memory (VBM) test and Visual Memory (VIM) test are measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of composite memory is calculated from results of these two tests. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

Secondary Outcome Measures

  1. The amount of change of the standardized score of composite memory between Base line and Week 12 [Base line and Week 12]

    VBM test and VIM test are measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of composite memory is calculated from results of these two tests. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  2. The measured value of the standardized score of neurocognition index (NCI) at Week 12 [Week 12]

    Seven neurocognitive tests {VBM, VIM, Finger Tapping (FTT), Symbol Digit Coding (SDC), Stroop Test (ST), Shifting Attention (SAT), and Continuous Performance (CPT)} are measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of NCI is calculated from results of these seven tests. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  3. The amount of change of the standardized score of NCI between Base line and Week 12 [Base line and Week 12]

    Seven neurocognitive tests {VBM, VIM, FTT, SDC, ST, SAT, and CPT} are measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of NCI is calculated from results of these seven tests. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  4. The measured value of the standardized score of verbal memory at Week 12 [Week 12]

    VBM test is measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of verbal memory is calculated from the result of this test. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  5. The amount of change of the standardized score of verbal memory between Base line and Week 12 [Base line and Week 12]

    VBM test is measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of verbal memory is calculated from the result of this test. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  6. The measured value of the standardized score of visual memory at Week 12 [Week 12]

    VIM test is measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of visual memory is calculated from the result of this test. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  7. The amount of change of the standardized score of visual memory between Base line and Week 12 [Base line and Week 12]

    VIM test is measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of visual memory is calculated from the result of this test. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  8. The measured value of the standardized score of psychomotor speed at Week 12 [Week 12]

    FTT test and SDC test are measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of psychomotor speed is calculated from results of these two tests. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  9. The amount of change of the standardized score of psychomotor speed between Base line and Week 12 [Base line and Week 12]

    FTT test and SDC test are measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of psychomotor speed is calculated from results of these two tests. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  10. The measured value of the standardized score of reaction time at Week 12 [Week 12]

    ST test is measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of reaction time is calculated from the result of this test. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  11. The amount of change of the standardized score of reaction time between Base line and Week 12 [Base line and Week 12]

    ST test is measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of reaction time is calculated from the result of this test. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  12. The measured value of the standardized score of complex attention at Week 12 [Week 12]

    ST test, SAT test, and CPT test are measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of complex attention is calculated from results of these three tests. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  13. The amount of change of the standardized score of complex attention between Base line and Week 12 [Base line and Week 12]

    ST test, SAT test, and CPT test are measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of complex attention is calculated from results of these three tests. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  14. The measured value of the standardized score of cognitive flexibility at Week 12 [Week 12]

    ST test and SAT test are measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of cognitive flexibility is calculated from results of these two tests. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  15. The amount of change of the standardized score of cognitive flexibility between Base line and Week 12 [Base line and Week 12]

    ST test and SAT test are measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of cognitive flexibility is calculated from results of these two tests. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  16. The measured value of the standardized score of processing speed at Week 12 [Week 12]

    SDC test is measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of processing speed is calculated from the result of this test. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  17. The amount of change of the standardized score of processing speed between Base line and Week 12 [Base line and Week 12]

    SDC test is measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of processing speed is calculated from the result of this test. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  18. The measured value of the standardized score of executive function at Week 12 [Week 12]

    SAT test is measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of executive function is calculated from the result of this test. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  19. The amount of change of the standardized score of executive function between Base line and Week 12 [Base line and Week 12]

    SAT test is measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of executive function is calculated from the result of this test. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  20. The measured value of the standardized score of social acuity at Week 12 [Week 12]

    Perception of Emotions (POET) test is measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of social acuity is calculated from the result of this test. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  21. The amount of change of the standardized score of social acuity between Base line and Week 12 [Base line and Week 12]

    POET test is measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of social acuity is calculated from the result of this test. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  22. The measured value of the standardized score of reasoning at Week 12 [Week 12]

    Non-Verbal Reasoning (NVRT) test is measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of reasoning is calculated from the result of this test. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  23. The amount of change of the standardized score of reasoning between Base line and Week 12 [Base line and Week 12]

    NVRT test is measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of reasoning is calculated from the result of this test. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  24. The measured value of the standardized score of working memory at Week 12 [Week 12]

    4-Part Continuous Performance (FPCPT) test is measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of working memory is calculated from the result of this test. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  25. The amount of change of the standardized score of working memory between Base line and Week 12 [Base line and Week 12]

    FPCPT test is measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of working memory is calculated from the result of this test. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  26. The measured value of the standardized score of sustained attention at Week 12 [Week 12]

    FPCPT test is measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of sustained attention is calculated from the result of this test. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  27. The amount of change of the standardized score of sustained attention between Base line and Week 12 [Base line and Week 12]

    FPCPT test is measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of sustained attention is calculated from the result of this test. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  28. The measured value of the standardized score of simple attention at Week 12 [Week 12]

    CPT test is measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of simple attention is calculated from the result of this test. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  29. The amount of change of the standardized score of simple attention between Base line and Week 12 [Base line and Week 12]

    CPT test is measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of simple attention is calculated from the result of this test. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  30. The measured value of the standardized score of motor speed at Week 12 [Week 12]

    FTT test is measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of motor speed is calculated from the result of this test. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

  31. The amount of change of the standardized score of motor speed between Base line and Week 12 [Base line and Week 12]

    FTT test is measured using Cognitrax® which is powered by CNS Vital Signs®, a neurocognitive test system. The standardized score of motor speed is calculated from the result of this test. This score has been normalized with a mean of 100 and a standard deviation of 15 based on age-matched reference data. Higher scores are always better.

Eligibility Criteria

Criteria

Ages Eligible for Study:
35 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Japanese

  2. Male and female

  3. Subjects aged 35-65

  4. Healthy subjects

  5. Subjects who notice a decline in memory

  6. Subjects whose scoring of Mini Mental State Examination (MMSE) is 24 or more

  7. Subjects who met the inclusion criteria 1. ~ 6. and have relatively low standardized score in composite memory measured using Cognitrax at Scr (Selection of those with relatively low standardized scores will be conducted in blocks of "Subjects aged 50 or over" and "Subjects aged under 50")

  8. Subjects who are judged as eligible to participate in the study by the physician

Exclusion Criteria:
  1. Subjects undergoing medical treatment or having a medical history of malignant tumor, heart failure, or myocardial infarction

  2. Subjects carrying a pacemaker or an implantable cardioverter defibrillator (ICD)

  3. Subjects undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disease, kidney disease, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases

  4. Subjects who have dementia

  5. Subjects who have mental health issues such as depression disorder, attention deficit/hyperactivity disorder (ADHD), or other issues

  6. Subjects who use or take "Foods for Specified Health Uses", "Foods with Function Claims", or other functional food/beverage, as part of their daily intake

  7. Subjects who take supplements or foods that may improve cognitive functions, such as phosphatidylserine, docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), ginkgo leaf extract, tocotrienol, astaxanthin, gamma-aminobutyric acid (GABA), and plasmalogen, as part of their daily intake

  8. Subjects who take blue-backed fish such as sardines, mackerel, and saury for 4 days/week or over

  9. Subjects who use devices, equipment, and applications that may affect cognitive functions (e.g., brain training puzzles, brain training games) as part of their daily life

  10. Subjects regularly taking medications (including herbal medicines) and supplements

  11. Subjects who are allergic to medications and/or the test food related products

  12. Subjects who are pregnant, breast-feeding or planning for pregnancy during the trial period

  13. Subjects who have been enrolled in other clinical trials 28 days before the agreement to participate in this trial or those who plan to enroll in another clinical trial during the trial period

  14. Subjects who are deemed ineligible to participate by the principal investigator

Contacts and Locations

Locations

Site City State Country Postal Code
1 Nerima Medical Association Minami-machi Clinic Nerima-ku Tokyo Japan 176-0002
2 Medical Corporation Seishinkai, Takara Clinic Shinagawa-ku Tokyo Japan 141-0022

Sponsors and Collaborators

  • Orthomedico Inc.
  • ECA Healthcare Inc.

Investigators

  • Principal Investigator: Tsuyoshi Takara, MD, Medical Corporation Seishinkai, Takara Clinic

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Orthomedico Inc.
ClinicalTrials.gov Identifier:
NCT05962008
Other Study ID Numbers:
  • 06788-0019-10
First Posted:
Jul 27, 2023
Last Update Posted:
Jul 27, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Orthomedico Inc.

Study Results

No Results Posted as of Jul 27, 2023